Vaginal and Urinary Microbiome Trial

Sponsor
University of Louisville (Other)
Overall Status
Completed
CT.gov ID
NCT02869165
Collaborator
(none)
110
1
2
35.9
3.1

Study Details

Study Description

Brief Summary

A randomized controlled trial looking at the effects of vaginal estrogen and a nonhormonal alternative on the vaginal and urinary microbiome in women with genitourinary syndrome of menopause.

Condition or Disease Intervention/Treatment Phase
  • Drug: Conjugated equine estrogen topical cream
  • Drug: Apricot kernel oil
Phase 4

Detailed Description

This is a study is looking at the effects of vaginal estrogen and a nonhormonal alternative on the vaginal and urinary microbiome in women with genitourinary syndrome of menopause. The primary objective is to describe the bacterial communities associated in the vagina and urine of postmenopausal women receiving treatment for genitourinary syndrome of menopause with conjugated equine estrogen topical cream (Premarin®) and a nonhormonal alternative (apricot kernel oil). The participants will be randomized to either conjugated equine estrogen topical vaginal cream or apricot kernel oil. They will be given validated questionnaires to assess their urinary and vaginal symptoms, sexual function, quality of life, and impressions of severity and improvement.

Study Design

Study Type:
Interventional
Actual Enrollment :
110 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
The Effects of Vaginal Estrogen and a Nonhormonal Alternative on the Vaginal and Urinary Microbiome in Women With Genitourinary Syndrome of Menopause: A Randomized Controlled Trial
Actual Study Start Date :
Jan 1, 2017
Actual Primary Completion Date :
Jun 30, 2018
Actual Study Completion Date :
Dec 31, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Conjugated equine estrogen topical cream

The conjugated equine estrogen topical vaginal cream 0.5 grams per vagina two times per week at nights for 3 months.

Drug: Conjugated equine estrogen topical cream
Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
Other Names:
  • Premarin vaginal cream
  • Vaginal estrogen cream
  • CEE topical cream
  • Experimental: Apricot kernel oil

    One teaspoonful per vagina every night for 3 months.

    Drug: Apricot kernel oil
    Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
    Other Names:
  • Natural oil
  • Organic oil
  • Outcome Measures

    Primary Outcome Measures

    1. Vaginal and urinary predominance of anaerobic/fastidious taxonomy of micro-organisms on genomic, microbial DNA analysis of vaginal and urinary specimens. [3 months]

      Predominance (greater than 50%) in vaginal and urinary specimen of anaerobic and/or fastidious organisms in the study population compared between conjugated equine estrogen cream (Premarin) and apricot kernel oil. The primary analysis will compare the prevalence of genomic taxonomic anaerobic and/or fastidious organism predominance (>50%) between the estrogen group and the non-estrogen alternative group.

    Secondary Outcome Measures

    1. Change in vaginal symptom questionnaire (VSQ) [3 months]

      Change in vaginal symptoms as assessed by vulvovaginal symptom questionnaire (VSQ) at baseline and after treatment.

    2. Vaginal and urinary predominance of anaerobic/fastidious taxonomy of micro-organisms on genomic, microbial DNA analysis of vaginal and urinary specimens. [3 months]

      Predominance (greater than 50%) in vaginal and urinary specimen of anaerobic and/or fastidious organisms in the study population compared between the conjugated equine estrogen cream (Premarin) and apricot kernel oil. The primary analysis will compare the prevalence of genomic taxonomic anaerobic and/or fastidious organism predominance (>50%) between the baseline patients and the patients at 3 months and compare the change in prevalence in this taxonomic predominance between the two study groups.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age 18-years old

    • Women who qualify for vaginal estrogen

    • Suitability for follow-up

    • Hormonally post-menopausal status: Bilateral past ovarian removal, ≥1 year since last menses if uterus in place, OR hysterectomized woman with ≥1 ovary in place AND >1 year of menopausal symptoms or laboratory confirmation of menopausal hormonal status (such as serum follicle stimulation hormone >25 IU/mL)

    • GSM symptoms (including, but not limited to genital symptoms of dryness, burning, itching, and irritation; sexual symptoms of lack of lubrication, discomfort or pain, and impaired sexual function; and urinary symptoms of urgency, frequency, dysuria and recurrent (UTIs)

    Exclusion Criteria:
    • Age < 18-years old

    • Known allergic reaction or other adverse reactions to Premarin® or any of its components or apricot kernel oil

    • Nut allergy

    • Inability to use or place vaginal therapy due to altered mental status or anatomical reasons

    • Already using vaginal estrogen or apricot kernel oil in the past two weeks

    • Known active vaginal infection (symptomatic and/or untreated) or completion of treatment for bacterial vaginosis or cervical/vaginal infection within one week of recruitment

    • History of recurrent or chronic bacterial vaginosis with > 2 episodes per year or symptoms reported for > 6 months out of the last year.

    • History of active vaginal ulcerative disease (active ulcers from atrophy, herpes symptoms at recruitment or herpes with >2 outbreaks per year or last outbreak <1month ago, or vaginal laceration.

    • Chronic antibiotic or probiotic use for indications not listed.

    • Pelvic organ prolapse beyond the hymenal ring

    • Using a vaginal pessary or indwelling urinary catheter

    • Evidence of active urinary tract infection by history and symptoms, urine dipstick, or urine culture on day of presentation or within last 2 weeks (defined as ≥ 100,000 colonies same pathologic bacteria on clean catch or 10,000 colonies on straight catheter specimen)

    • Recurrent urinary tract infection 3 episodes with the last year or 2 episodes within the last 6 months.

    • History of venous or arterial thromboembolism or genetic predisposition to thromboembolism.

    • Ovarian cancer and estrogen responsive cancer including endometrial or breast or breast cancer history of unknown hormonal status

    • Vaginal mesh erosion, sutures visible in the vagina or granulation tissue

    • Uncorrected vesicovaginal or rectovaginal fistula

    • Severe fecal or anal incontinence

    • Active vulvar dermatoses (lichen sclerosis, Behcet's disease, vulvar eczema) and on chronic topical steroids.

    • Subjects with absolute contraindications to estrogen, such as diabetes mellitus with end-organ damage and vascular disease, impaired liver function or a hepatic hemangioma, chronic renal disease, migraine with aura, systemic lupus erythematosus with prior thrombosis or vascular damage or other end-organ damage

    • Patients < 6 weeks postop

    • Inability to speak or read English

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Health Care Outpatient Center and Springs Medical Center Louisville Kentucky United States 40202 and 40205

    Sponsors and Collaborators

    • University of Louisville

    Investigators

    • Principal Investigator: Deslyn Hobson, M.D., University of Louisville School of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Deslyn T. Hobson, Fellow Female Pelvic Medicine and Reconstructive Surgery, University of Louisville
    ClinicalTrials.gov Identifier:
    NCT02869165
    Other Study ID Numbers:
    • 16.0428
    First Posted:
    Aug 16, 2016
    Last Update Posted:
    May 18, 2021
    Last Verified:
    May 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Deslyn T. Hobson, Fellow Female Pelvic Medicine and Reconstructive Surgery, University of Louisville
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 18, 2021